ArticleClinical and translational science2023

A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib.

Ling Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.